Endo, which makes both brand-name and generic drugs, is set on increasing its generics portfolio and sees the acquisition of DAVA as a ‘natural fit’ for Endo’s generics business. DAVA has an attractive existing commercial portfolio and near-term pipeline, according to Endo.

DAVA operates a highly profitable generics franchise with 2013 revenue of approximately US$131 million and 2013 adjusted earnings of approximately US$100 million. The company DAVA's portfolio includes 13 marketed products in a variety of therapeutic areas. In addition, DAVA also has a promising product pipeline across a multitude of therapeutic categories, including recent launches of generic versions of the antibiotics doxycycline and cefdinir. The company also expects to launch more than five products in 2015 and more than 20 additional products in the coming years.

This is not the first purchase Endo has made in the generics arena. The company bought specialty generics maker Boca Pharmacal (Boca) for US$225 million in August 2013 [1].

The current acquisition is also likely not to be Endo’s last in this area. Endo’s President and CEO, Mr Rajiv De Silva, said that ‘strategic acquisitions will continue to play a key role in maximizing our growth potential’.

Related articles
FDA rejects Endo petition to stop Opana ER generics

Endo acquires US generics’ giant Qualitest

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Endo to buy specialty generics drugmaker Boca Pharmacal [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Aug 1]. Available from: www.gabionline.net/Pharma-News/Endo-to-buy-specialty-generic-drugmaker-Boca-Pharmacal

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.